XTL BIOPHARMACEUTICALS LTD.

Highlights XTL Biopharmaceuticals Ltd. Nasdaq

Equities

XTLB

US98386D3070

Market Closed - Nasdaq Other stock markets 21:30:01 28/05/2024 BST			5-day change	1st Jan Change
2.61 ^USD	0.00%		-6.79%	+158.39%

04-30	XTL Biopharmaceuticals Ltd. Reports Earnings Results for the Full Year Ended December 31, 2023	CI
04-29	Top Premarket Gainers	MT

Highlights

Unlock all the news on all businesses: Never miss an investment opportunity again!

100% Free Registration

XTL Biopharmaceuticals Ltd. Reports Earnings Results for the Full Year Ended December 31, 2023	04-30	CI
Top Premarket Gainers	04-29	MT
Top Midday Gainers	03-20	MT
XTL Biopharmaceuticals to Acquire The Social Proxy; Shares Soar	03-20	MT
XTL Biopharmaceuticals Ltd. entered into a binding term sheet to acquire THE SOCIAL PROXY Ltd.	03-19	CI
XTL Biopharmaceuticals Ltd. Reports Earnings Results for the Nine Months Ended September 30, 2023	11-15	CI
XTL Biopharmaceuticals Ltd. Unveils Expanded hCDR1 Preclinical Data for the Treatment of Sjögren’s Syndrome	05/04/17	CI
XTL Biopharmaceuticals Ltd. Reports Audited Consolidated Earnings Results for the Full Year Ended December 31, 2016	30/03/17	CI
XTL Biopharmaceuticals Ltd. Announces Unaudited Consolidated Earnings Results for the Third Quarter and Nine Months Ended September 30, 2016	06/12/16	CI
XTL Biopharmaceuticals Ltd. Announces Unaudited Consolidated Earnings Results for the Second Quarter and Six Months Ended June 30, 2016	27/09/16	CI
XTL Biopharmaceuticals Announces New Patent Filing in U.S. for Lupus Drug hCDR1	11/08/16	CI
XTL Biopharmaceuticals Ltd. Announces Consolidated Earnings Results for the First Quarter Ended March 31, 2016	01/06/16	CI

No results for this search

All News Analyst Reco. Highlights Insiders Transcripts Press Releases Official Publications Other languages Trading Ideas MarketScreener Editorial Features MarketScreener Strategies

Filters

Like the pros, access all the transcripts and spot the best opportunities before anyone else.

Unlock them now!

fermer